China's medical products administrator granted Hutchmed (HKG:0013) breakthrough therapy designation for its combination of savolitinib and osimertinib for a mutation of non-small cell lung cancer, according to a Thursday filing with the Hong Kong Exchange.
The drug combination is undergoing phase 3 trials in China, the filing said.
The breakthrough designation is given to drugs that treat life-threatening illnesses with no known treatment options and with clinical evidence showing advantages over other existing therapies, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments